Commentary

Video

Factors That Influence Treatment Decisions in Later-Line CML

Author(s):

Javier Pinilla, MD, PhD,Talha Badar, MBBS, MD

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Andrew Kuykendall, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Shaji Kumar, MD
Shaji Kumar, MD
Related Content
S. Vincent Rajkumar, MD
December 17th 2024

Research Shows New Treatment Could Delay Cancer Progression in Patients With High-Risk Smoldering Multiple Myeloma

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

ASH Annual meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 13th 2024

100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Ponatinib Risk Management in CML/ALL | Image Credit: © ivlianna stock.adobe.com
December 11th 2024

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

HMA-Naive Chronic Myelomonocytic Leukemia | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia